Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the rituximab biosimilars market grown over the years?

The market for rituximab biosimilars has experienced expedited expansion in recent times. It’s projected to increase from $3.03 billion in 2024 to $3.47 billion in 2025, reflecting a compound annual growth rate (CAGR) of 14.8%. The previous growth is ascribed to factors such as, government ventures, escalated healthcare spending, a growth in expenditure on biopharmaceutical R&D, affordability of biosimilars, and the rise of emerging markets.

What Is the forecasted market size and growth rate for the rituximab biosimilars market?

In the coming years, the nail polish market is anticipated to witness a swift expansion. It is projected to escalate to a value of $25.35 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 12.0%. The growth during the prediction period could be a result of investment in research and development, global market expansion, digital marketing tactics, ethically-conscious and eco-friendly goods, and evolving consumer tastes and trends. Predominant trends for the forecast timeframe comprise retail and distribution approaches, wave towards vegan and cruelty-free products, fashion and runway impacts, product personalization and customization, along with advances in the composition and elements of the products.

Get your rituximab biosimilars market report here!

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

What are the major factors driving growth in the rituximab biosimilars market?

The anticipated increase in cases of non-Hodgkin’s lymphoma (NHL) stands to fuel the expansion of the rituximab biosimilars market. Non-Hodgkin’s lymphoma is a cancer type which originates in the body’s white blood cells, specifically lymphocytes that compose part of the immune system. To illustrate, the American Cancer Society, a US-based cancer advocacy group, stated in January 2024 that approximately 80,620 people (comprising 44,590 men and 36,030 women) are projected to be diagnosed with non-Hodgkin lymphoma in 2024. Correspondingly, it is estimated that there will be 20,140 deaths (11,780 men and 8,360 women) from this cancer during this year. The lifetime risk of acquiring this form of cancer is approximately 1 in 42 for men and 1 in 52 for women. Therefore, the increasing incidence of non-Hodgkin’s lymphoma is foreseen to result in augmented demand for rituximab biosimilars during the forecast period.

What key areas define the segmentation of the global rituximab biosimilars Market?

The rituximab biosimilars market covered in this report is segmented –

1) By Route Of Administration: Subcutaneous, Intravenous, Molecular Type

2) By Application: Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Mail Order

Subsegments:

1) By Subcutaneous: Pre-filled Syringes, Injection Pens

2) By Intravenous: IV Infusion Solutions, IV Push Formulations

3) By Molecular Type: Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3430&type=smp

What are the top market players propelling the growth of the rituximab biosimilars industry?

Major companies operating in the rituximab biosimilars market include Novartis AG, Pfizer, BIOCAD, Shanghai Henlius Biotech Inc., Innovent Biologics Inc., Sinocelltech, Cadila Pharmaceuticals, Hetero Drugs Limited, Dr. Reddy’s Laboratories, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Reliance Life Sciences India, Zenotech Laboratories, NAPP Pharmaceuticals Limited, Mundipharma Deutschland GmbH & Co. KG, Celltrion, Biocad, MABION S.A., Janssen Pharmaceutical, Amgen, Teva Pharmaceuticals, Celltrion Healthcare, Coherus BioSciences, Aryogen Biopharma, TR-Pharm, Hikma Pharmaceuticals plc.

What are the key trends shaping the future of the rituximab biosimilars market?

Firms active in the biosimilars sector are persistently focused on the development of new products, often partnering with other businesses within the sector to drive innovation. The rituximab biosimilars market is being shaped by these collaborative efforts. To exemplify, in July 2023, Dr. Reddy’s Laboratories joined forces with Fresenius Kabi to bring their intended biosimilar of rituximab to the US market. The primary objective of this partnership is to create a more cost-effective and easily available treatment option by introducing a biosimilar version of rituximab. Introducing a biosimilar version of rituximab in the US could potentially enhance the accessibility of this vital treatment for patients suffering from various health conditions, such as rheumatoid arthritis, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis, and microscopic polyangiitis.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3430

What regions are dominating the rituximab biosimilars market growth?

North America was the largest region in the rituximab biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the rituximab biosimilars market report during the forecast period. The regions covered in the rituximab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Biosimilar Hormones Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Generic Pharmaceuticals Global Market Opportunities And Strategies To 2033

https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-market

Oncology Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: